Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer-Reference-Cited by-同舟云学术

Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer

Published:2016-06-06 Issue:1 Volume:16 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Tominaga Tetsuro,Tsuchiya Tomoshi,Mochinaga Koji,Arai Junichi,Yamasaki Naoya,Matsumoto Keitaro,Miyazaki Takuro,Nagasaki Toshiya,Nanashima Atsushi,Tsukamoto Kazuhiro,Nagayasu Takeshi

Funder

Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-016-2392-0

Reference32 articles.

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.

2. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.

3. Thatcher N, Chang A, Parikh P, Rodriques PJ, Ciuleanu T, Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–37.

4. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513–20.

5. Morita S, Hirashima T, Hagiwara K, Hida T, Sunaga K, Sugio A, et al. I-CAMP Study Group Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials ASCO Annual Meeting Proceedings. J Clin Oncol. 2008;26:8101.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of epidermal growth factor receptor mutation on adjuvant chemotherapy with tegafur/uracil for patients with completely resected, non-lymph node metastatic non-small cell lung cancer (> 2 cm): a multicenter, retrospective, observational study as exploratory analysis of the CSPOR-LC03 study;Japanese Journal of Clinical Oncology;2024-09-11

2. The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review;Critical Reviews in Oncology/Hematology;2024-02

3. Effect of Tegafur–Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study;Annals of Thoracic and Cardiovascular Surgery;2024-01-26

4. Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced Colorectal Cancer Patients: An Exploratory Study;Current Oncology;2024-01-03

5. Aureolic Acid-Derived Antibiotics: Prospects for a Biologically Active Class;Russian Journal of Bioorganic Chemistry;2022-04